secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001193125-25-230926
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Maze appoints ex-Incyte CEO Hervé Hoppenot as Chairman, effective Oct 6
-----------------------------------------------------------------------

- Hervé Hoppenot appointed Class II director and Chairman of the Board, succeeding Charles Homcy, who remains a director.
- Hoppenot served as Incyte CEO (2014-2025) and Chairman (2015-2025); also on boards of Bicycle Therapeutics and Laboratoires Pierre Fabre.
- Receives pro rata portions of $40k director retainer and $30k Chairman retainer; granted option for 36,000 shares vesting over 36 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312525230926/0001193125-25-230926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312525230926/d84372d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-230926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer